AMENDMENT NO. 1 TO THE MARKETING, DISTRIBUTION AND SUPPLY AGREEMENTAnd Supply Agreement • November 9th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL...And Supply Agreement • May 9th, 2014 • GoPro, Inc. • Photographic equipment & supplies • California
This Design, Manufacturing and Supply Agreement (this “Agreement”) is made as of August 18, 2011 (the “Effective Date”), by and between Woodman Labs, Inc. (d/b/a GoPro), a California corporation with offices at 2450 Cabrillo Highway South, Suite 250, Half Moon Bay, California 94109 USA (“Customer”), and Chicony Electronics Co. Ltd., a Taiwan corporation with offices at No.25, Wu-Gong 6th Rd., Wu Ku Industrial Park, New Taipei City, R.O.C. (“Manufacturer”). Customer and Manufacturer are each referred to as a “Party” and are collectively referred to as the “Parties.”
EX-10.10 9 d641160dex1010.htm EX-10.10 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act...And Supply Agreement • May 5th, 2020
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Agreement”), dated as of August 1st, 2013, is entered into by and between R-Pharm, CJSC, a corporation organized and existing under the laws of the Russian Federation, having offices located at 12 Bld. 1, Nagorny Proezd, Moscow, Russian Federation (“R-Pharm”), and Scynexis, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 3501C Tricenter Boulevard, Durham North Carolina, USA 27713 (“Scynexis”).
EX-10.8 13 d411577dex108.htm CLINICAL AND COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT Portions Subject to Confidential Treatment Request Under Rule 24b-2 CLINICAL AND COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTAnd Supply Agreement • May 5th, 2020
THIS CLINICAL AND COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made effective as of the 22nd day of December, 2010 (“Effective Date”) by and between BAXTER ONCOLOGY GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany (“Baxter”) and CELATOR PHARMACEUTICALS, INC., a Delaware corporation, having offices at 303B College Road East, Princeton, New Jersey 08540 (“Celator”).
FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENTAnd Supply Agreement • February 27th, 2009 • Allergan Inc • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENT (this “Amendment”), dated as of January 9, 2009 (the “Amendment Effective Date”), is entered into by and among Indevus Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 33 Hayden Avenue, Lexington, MA 02421 (“Indevus”), and Allergan USA, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 2525 Dupont Drive, Irvine, CA 92612 (f/k/a Esprit Pharma, Inc.) (“Allergan”). Indevus and Allergan are collectively referred to herein as the “Parties”.
THE USE OF THE FOLLOWING NOTATION IN THIS EXHIBIT INDICATES THAT THE CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATEMENT AND THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE...And Supply Agreement • May 9th, 2013 • Gogo Inc. • Communications services, nec
This Amendment No. 2 to the Manufacturing Services and Product Supply Agreement (this “Amendment No. 2”) is made and entered into as of April 8, 2011 (the “Amendment No. 2 Effective Date”) by and between QUALCOMM Incorporated having a place of business at 5775 Morehouse Drive, San Diego, California, 92121 (“QUALCOMM”), and AIRCELL LLC, a Delaware limited liability company, having a place of business at 1250 North Arlington Heights Rd. Suite 500, Itasca, IL 60143 (“Customer”).
Manufacturing and Supply Agreement (Projekt H 2000)And Supply Agreement • February 6th, 2018 • Biofrontera AG • Pharmaceutical preparations
This Manufacturing and Supply Agreement (together with its Attachments, which are incorporated herein by reference, the "Agreement") is made on June 1st, 2015 (the "Effective Date") by and between Hapila GmbH, Otto-Schott-Straße 9, 07552 Gera, Germany ("Hapila") and Biofrontera Pharma GmbH, HemmelratherWeg 201, D-51377 Leverkusen, Germany ("Biofrontera"). Hapila and Biofrontera are hereinafter also referred to individually as "Party" or collectively as "Parties".
EX-4.16 6 exhibit_4-16.htm Confidential treatment requested as to portions of this agreement, which were omitted and filed separately with the Securities and Exchange Commission ORIGINAL DESIGN, MANUFACTURE AND SUPPLY AGREEMENT By and Between AND Crow...And Supply Agreement • May 5th, 2020
THIS ORIGINAL DESIGN MANUFACTURE AND SUPPLY AGREEMENT (“Agreement”) is entered into as of the ____ day of _____________, 2006, between Crow Electronic Engineering LTD, an Israeli company organized under the laws of the State of Israel, having its main place of business at 12 Kineret Street, Airport City, Israel(“Original Design Manufacturer” or “ODM”) and *** (a division of ****), a company organized under the laws of *** (“***”). ODM and *** shall be referred collectively as “Parties” or individually as “Party.” Unless otherwise noted, all capitalized terms in this Agreement shall have the meanings set forth in Article 1.
RESTATED COMMUNICATING THERMOSTAT CO-DEVELOPMENT AND SUPPLY AGREEMENTAnd Supply Agreement • January 3rd, 2007 • Comverge, Inc. • Auto controls for regulating residential & comml environments • Missouri
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES...And Supply Agreement • September 9th, 2011 • Coronado Biosciences Inc • Pharmaceutical preparations
This Manufacturing and Supply Agreement (the “Agreement”) is entered into this day of December, 2005 (the “Effective Date”), by and between Collingwood Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 787 Seventh Avenue, 48th Floor, New York, New York 10019 (“Collingwood”), and Ovamed GmbH, a corporation organized and existing under the laws of Germany and having a principal place of business at Kiebitzhörn 33-35, 22885 Barsbüttel, Germany (“Ovamed”). Collingwood and Ovamed may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Third Amendment to Pharmaceutical Manufacturing and Supply AgreementAnd Supply Agreement • March 16th, 2017 • Omeros Corp • Pharmaceutical preparations
This is an Amendment (this “Amendment”) to the Pharmaceutical Manufacturing and Supply Agreement dated March 5, 2014, as previously amended July 7, 2015 and August 24, 2016 between DSM Pharmaceuticals, Inc. (“DSM”) and Omeros Corporation (“Omeros”) (the “Master Agreement”), and is entered into as of December 05, 2016 (the “Amendment Effective Date”). All initially capitalized terms in this Amendment shall have the same meaning as set forth in the Master Agreement unless otherwise defined herein.
MANUFACTURE AND SUPPLY AGREEMENTAnd Supply Agreement • August 7th, 2008 • Acclarent Inc • Surgical & medical instruments & apparatus • New Hampshire
THIS MANUFACTURE AND SUPPLY AGREEMENT is made as of September 8, 2005 (the “Effective Date”), by and between ACCLARENT, INC., a Delaware Corporation with a principal place of business in Menlo Park, California, and with a mailing address of 1525-B O’Brien Drive, Menlo Park, California, 94025 (hereinafter referred to as Acclarent), and ADVANCED POLYMERS, INC., a New Hampshire corporation duly organized and existing under the laws of the State of New Hampshire, having its principal place of business in Salem, New Hampshire, and with a mailing address of 29 Northwestern Drive, Salem, New Hampshire, 03079, (hereinafter referred to as Advanced).
AMENDED AND RESTATED DEVELOPMENT, MANUFACTURING, LICENSING AND SUPPLY AGREEMENTAnd Supply Agreement • March 9th, 2010 • Dexcom Inc • Surgical & medical instruments & apparatus • California
Manufacturing and Supply AgreementAnd Supply Agreement • May 10th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENTAnd Supply Agreement • November 15th, 2010 • diaDexus, Inc. • Pharmaceutical preparations
This first amendment (the “First Amendment”) to DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT (the “Agreement”) is made effective as of July 21, 2008, 2008 (the “Amendment Effective Date”) by and between DIADEXUS, INC., organized under the laws of Delaware and having its principal place of business at 343 Oyster Point Boulevard, South San Francisco, California 94080, United States of America (“diaDexus”), and DENKA SEIKEN, organized under the laws of Japan and having its principal place of business at 3-4-2 Nihonbashi Kayabacho, Chuo-ku, Tokyo 103-0025, Japan (“Denka Seiken”).
First Amendment to Manufacturing and Supply AgreementAnd Supply Agreement • June 11th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to the Manufacturing and Supply Agreement (this “Amendment”) is made as of the 21 of May, 2012 (the “Effective Date of this Amendment”) by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware, with offices at 235 E. 42nd Street, New York, NY 10017 (“Pfizer”) and Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having an address of 27200 Agoura Road, Calabasas, California 91301 (hereinafter “Customer”).
DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT, and Supply Agreement • November 15th, 2010 • diaDexus, Inc. • Pharmaceutical preparations • California
THIS DEVELOPMENT, MANUFACTURING, AND SUPPLY AGREEMENT, together with exhibits attached hereto (the “Agreement”), effective as of March 27th, 2007 (the “Effective Date”), is entered into by and between DIADEXUS, INC., organized under the laws of Delaware and having its principal place of business at 343 Oyster Point Boulevard, South San Francisco, California 94080, United States of America (“diaDexus”), and DENKA SEIKEN, organized under the laws of Japan and having its principal place of business at 3-4-2 Nihonbashi Kayabacho, Chuo-ku, Tokyo 103-0025, Japan (“Denka Seiken”). diaDexus and Denka Seiken may each be referred to herein individually as a “Party” or, collectively, as “Parties.”
Amendment No. 2 to Manufacturing and Supply AgreementAnd Supply Agreement • August 2nd, 2018 • Nevro Corp • Surgical & medical instruments & apparatus
Amendment No. 2 to the Manufacturing and Supply Agreement, dated ___ April, 2018 (the “Amendment”) between Nevro Corp. (“Nevro”) and Nordson MEDICAL Design and Development, Inc., fka Vention Medical Design and Development, Inc. (“Nordson MEDICAL”).
Alkermes Controlled Therapeutics Inc. II Cambridge, MA 02139 USAAnd Supply Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations
Pursuant to that certain Manufacturing and Supply Agreement (the “Agreement”), dated August 6, 1997, among Alkermes Controlled Therapeutics Inc. II (“ACT II”), JPI Pharmaceutica International, a division of Cilag AG International Zug, a company organized under the laws of Switzerland (“JPI”), and Janssen Pharmaceutica Inc. (“Janssen US”) (JPI and Janssen US collectively referred to herein as “Janssen”), as supplemented by that certain Addendum to Manufacturing and Supply Agreement (the “Addendum”), dated August 1, 2001, among ACT II, JPI and Janssen, certain exhibits referred to in the Agreement would be agreed to by the parties in the future. Those exhibits are Exhibits A, B, E, F, G and H. This letter sets forth the agreement by the parties as to such Exhibits.
MANUFACTURING AND SUPPLYAnd Supply Agreement • September 3rd, 2020 • Myos Rens Technology Inc. • Pharmaceutical preparations • Ontario
MedAvail Technologies Inc. (the “CUSTOMER”) a company incorporated and organized under the laws of Ontario with a registered office at: #1 - 6665 Millcreek Dr. Mississauga, Ontario L5N 5M4
AND SUPPLY AGREEMENTAnd Supply Agreement • March 30th, 2016 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
This Master Process Development and Supply Agreement (“Agreement”) by and between CELLSCRIPT, LLC (“CELLSCRIPT”), a Wisconsin limited liability company located at 726 Post Road, Madison, Wisconsin 53713, and Argos Therapeutics, Inc. (“Argos”), a Delaware corporation with a place of business located at 4233 Technology Drive, Durham, North Carolina 27704. CELLSCRIPT and Argos are also hereinafter each referred to as a “Party” or collectively referred to as the “Parties”.
AMENDMENT NO. 1 TO THE MANUFACTURING SERVICES AND SUPPLY AGREEMENTAnd Supply Agreement • March 22nd, 2012 • Gogo Inc. • Communications services, nec
This Amendment No. 1 to the Manufacturing Services and Product Supply Agreement (this “Amendment No. 1”) is made and entered into as of March 3, 2010 (the “Amendment No. 1 Effective Date”) by and between QUALCOMM Incorporated having a place of business at 5775 Morehouse Drive, San Diego, California, 92121 (“QUALCOMM”), and AIRCELL LLC, a Delaware limited liability company, having a place of business at 1250 North Arlington Heights Rd. Suite 500, Itasca, IL 60143 (“Customer”).
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions, marked by [***], have been separately filed with the Securities and Exchange Commission. FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING...And Supply Agreement • July 23rd, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This First Amendment to Development, Manufacturing and Supply Agreement (the “Agreement Amendment”) dated as of August 15, 2006 (the “Effective Date”) between Kensey Nash Corporation, a Delaware corporation, having its principal place of business at 735 Pennsylvania Avenue, Exton, PA 19341 (hereinafter referred to as “KNC”) and BioMimetic Therapeutics, Inc. (formerly, BioMimetic Pharmaceuticals Inc.), a Delaware corporation, having its principal place of business at 389-A Nichol Mill Lane, Franklin, TN 37067 (hereinafter referred to as “BMPI”).
CO-DEVELOPMENT, CO-OWNERSHIP ---------------------------- AND SUPPLY AGREEMENT --------------------And Supply Agreement • May 23rd, 2006 • Franklin Wireless Corp • Computer communications equipment
Amendment #2 to Manufacturing and Supply AgreementAnd Supply Agreement • March 14th, 2024 • UroGen Pharma Ltd. • Pharmaceutical preparations
This Amendment #2 to the Manufacturing & Supply Agreement (“Amendment #2”), effective as off its date of last signature (“Amendment #2 Effective Date”), is by and between UroGen Pharma Ltd., a company organized and existing under the laws of the State of Israel having an address at 9 HaTaasia St., Ra’anana 4365007, Israel (“Customer”) and Cenexi-Laboratoires Thissen S.A., a company incorporated in Belgium,having its registered office at 2-4-6, Rue de la Papyrée, B-1420 Braine-l'Alleud, also acting hereunder on behalf of its Affiliates ("Manufacturer").
CLINICAL AND COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTAnd Supply Agreement • February 27th, 2018 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations
THIS CLINICAL AND COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made effective as of the 22nd day of December, 2010 (“Effective Date”) by and between BAXTER ONCOLOGY GmbH, with an address at Kantstrasse 2, 33790 Halle / Westphalia, Germany (“Baxter”) and CELATOR PHARMACEUTICALS, INC., a Delaware corporation, having offices at 303B College Road East, Princeton, New Jersey 08540 (“Celator”).
ContractAnd Supply Agreement • January 15th, 2010
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTAnd Supply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This License, Development and Supply Agreement (the “Agreement”) is entered into as of October 8, 2014 (the “Effective Date”) by and between Spectrum Pharmaceuticals inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”).
MANUFACTURING LICENSE, TECHNICAL ASSISTANCE AND SUPPLY AGREEMENTAnd Supply Agreement • September 8th, 2008 • Manitou BF S.A. • Farm machinery & equipment • Wisconsin
This Agreement is entered into this 22nd day of July, 2004 (hereinafter, the “Effective Date”) by and between Manitou BF S.A. (hereinafter, “Licensor”), a corporation organized and existing under the laws of France and having its principal offices at ZI 430 route de l’Aubiniere, BP 249, F-44158 Ancenis cedex, France, and Gehl Company (hereinafter, “Licensee”), a corporation organized and existing under the laws of the State of Wisconsin, U.S. and having its principal offices at 143 Water Street, West Bend, Wisconsin 53095.
AMENDMENT NO. 1 TO LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENTAnd Supply Agreement • May 10th, 2005 • Indevus Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment”), dated as of April 30, 2005 (the “Amendment Effective Date”), by and between Indevus Pharmaceuticals, Inc. (“Indevus”) and Odyssey Pharmaceuticals, Inc. (“Odyssey”), amends that certain License, Commercialization and Supply Agreement, dated as of April 6, 2004 (the “Agreement”), by and between Indevus and Odyssey.
Amendment No. 1 to Manufacturing and Supply AgreementAnd Supply Agreement • May 4th, 2016 • Relypsa Inc • Pharmaceutical preparations
This Amendment No. 1 to the Manufacturing and Supply Agreement (“Amendment No. 1”) is made and entered into effective as of March 7, 2016 (the “Amendment No. 1 Effective Date”) by and between RELYPSA, INC., a Delaware corporation, located at 100 Cardinal Way, Redwood City, CA 94063 (“RELYPSA”) and DPx FINE CHEMICALS AUSTRIA GMBH & CO KG (formerly known as DSM Fine Chemicals Austria NFG GMBH & CO KG), with an address at Sankt-Peter-Straße 25, A-4020 Linz, Austria (“PATHEON”).
THIRD AMENDMENT Manufacturing and Supply Agreement between W.R. Grace & Co.-Conn. and ChromaDex, Inc.And Supply Agreement • November 4th, 2020 • ChromaDex Corp. • Medicinal chemicals & botanical products
This Third Amendment to the Manufacturing and Supply Agreement (the “Third Amendment”) is made and effective as of January 1, 2019 (the “Third Amendment Effective Date”) by and between W. R. Grace & Co.-Conn. (“GRACE”) and ChromaDex, Inc. (“ChromaDex”).
Wafer Manufacturing and Supply AgreementAnd Supply Agreement • August 14th, 2007 • Wj Communications Inc • Special industry machinery, nec • California
This Wafer Manufacturing and Supply Agreement (“Agreement”) is made and entered into this day of May, 2007, by and between Amptech, Inc., a Delaware corporation having its principal place of business at 5776-D Lindero Canyon Road, #431, Westlake Village, California 91362 (hereinafter “AMPTECH”) and WJ Communications, Inc., a Delaware corporation having its principal place of business at 401 River Oaks Parkway San Jose, CA 95134 (hereinafter “WJ”). (WJ and AMPTECH shall also sometimes be referred to herein together as the “Parties” or individually as a “Party”).
FIFTH AMENDMENT Manufacturing and Supply Agreement between W.And Supply Agreement • November 4th, 2020 • ChromaDex Corp. • Medicinal chemicals & botanical products
This Fifth Amendment to the Manufacturing and Supply Agreement (the “Fifth Amendment”) is made and effective as of January 1, 2020 (the “Fifth Amendment Effective Date”) by and between W. R. Grace & Co.—Conn. (“GRACE”) and ChromaDex. Inc. (“ChromaDex”).
COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENTAnd Supply Agreement • May 10th, 2023 • IVERIC Bio, Inc. • Pharmaceutical preparations • New York
This Commercial Manufacturing and Supply Agreement (this “Agreement”) is entered into by and between AGILENT TECHNOLOGIES, INC., a Delaware corporation, having a principal office at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”) and IVERIC BIO, INC., a Delaware corporation, having a principal office at 8 Sylvan Way, Parsippany, NJ 07054 (“Customer”) effective as of March 14, 2023 (the “Effective Date”). Agilent and Customer are each referred to herein as a “Party” and together as the “Parties”.
